The invention relates to 55 newly discovered proteins, which are present in isolated purified protein complexes, derived medicinal products, recombinant DNA, engineered DNA, cDNA, monoclonal and natural products or synthesized products as part of nutrition, food, and/or supplemental products and their applications.

This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory T cells (Treg) and associated compositions for the induction of immune tolerance are described. The methods and uses may be used to prevent transplant rejection, and in the treatment of diseases or conditions such as graft versus host disease, autoimmune disease and allergies. Also provided are transgenic mice that ubiquitously express FGL2 protein from which the Treg may be isolated.

The present invention relates to a method for preparing a protein cage which comprises: a 1.sup.st step of preparing an amphiphilic polymer comprising a 1.sup.st hydrophobic polymer and a 1.sup.st hydrophilic functional group; a 2.sup.nd step of preparing a hydrophilic protein comprising a 2.sup.nd functional group binding to the 1.sup.st functional group; a 3.sup.rd step of forming an amphiphilic polymer-protein hybrid by the binding of the 1.sup.st functional group and the 2.sup.nd functional group, and forming core-shell structured particles comprising a protein shell and an amphiphilic polymer core by the self-assembly of the amphiphilic polymer in a hydrophilic solvent; and a fourth step of removing some or all of the hydrophobic polymer of the core part from the core-shell structured particles.

The present invention relates to a method for preparing a protein cage which comprises: a 1.sup.st step of preparing an amphiphilic polymer comprising a 1.sup.st hydrophobic polymer and a 1.sup.st hydrophilic functional group; a 2.sup.nd step of preparing a hydrophilic protein comprising a 2.sup.nd functional group binding to the 1.sup.st functional group; a 3.sup.rd step of forming an amphiphilic polymer-protein hybrid by the binding of the 1.sup.st functional group and the 2.sup.nd functional group, and forming core-shell structured particles comprising a protein shell and an amphiphilic polymer core by the self-assembly of the amphiphilic polymer in a hydrophilic solvent; and a fourth step of removing some or all of the hydrophobic polymer of the core part from the core-shell structured particles.

The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.

The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.

The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of disclosed methods. The covalently modified biological macromolecules may be further crosslinked to form a scaffold.

The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of disclosed methods. The covalently modified biological macromolecules may be further crosslinked to form a scaffold.

Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.

Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.